Page 24 - NAMAH-Apr-2018

Namah Vol. 26, Issue 1, 24th April 2018

Multiple Both 4g. and 8g. daily A double-blind placebo-
myeloma doses reduced the serum controlled cross-over
free light chain ratio (35% of 19 patients with
and 36%, respectively) MGUS and 17 patients
and reduced total serum with smouldering MM
protein (P=0.04) in the urine examined the effects of
in both MGUS and SMM daily curcumin.
patients Curcumin also
decreased markers of bone
turnover (urinary DPYD)
and excretion of crosslinked
N-telopeptides by more
than 25% (23).
Pancreatic 12 months There was improvement 8 g. curcumin with
cancer of chemotherapy-related gemcitabine (Gemzar).
symptoms after starting
curcumin. The median
survival after initiation of
curcumin was 161 days.
One-year survival rate was
19%. Median survival after
gemcitabine is 70 days (24).
Prostate 6 months Isoflavones and curcumin 100 mg. of curcumin and
cancer could modulate serum 40 mg of isoflavones;
PSA levels. The authors and placebo.
of this study concluded
that curcumin presumably
synergizes with isoflavones
to suppress PSA production
(25).

Other inflammatory diseases: select clinical findings
Other inflammatory diseases: select clinical data
Disease Duration, Benefit Dosage
below
Arthritis 8 months Improved joint pain, Curcuminoid and
stiffness, physical phosphotidylcholine 1000 mg.
function, social and curcuma extract 200 curcuma
emotional function (26). extract daily.
Standard conventional treatment.

24